Liquidia Corporation's Upcoming Presentation
Liquidia Corporation (NASDAQ: LQDA) is set to take part in a significant event that highlights advancements in healthcare. The company’s Chief Executive Officer, Dr. Roger Jeffs, alongside Chief Financial Officer and Chief Operating Officer Michael Kaseta, and Chief Business Officer Jason Adair, will engage in a fireside chat during the much-anticipated Jefferies Global Healthcare Conference. This live interaction is scheduled for June, where the team will discuss the company's latest business developments.
Event Details
The Jefferies Global Healthcare Conference is known for bringing together thought leaders and innovators in healthcare. Liquidia's presentation will begin promptly at 11:05 a.m. ET. Attendees, including investors and stakeholders, will have the opportunity to gain insights into Liquidia’s strategic direction and growth initiatives. The session is designed to foster direct communication between the company and its investors, ensuring clarity and transparency.
Accessing the Webcast
In today's digital age, accessibility for all interested parties is crucial. Liquidia will provide a webcast of the presentation, which will be available on their official website. This ensures that those who cannot attend in person can still stay informed about the company’s progress and developments. Furthermore, a recorded version of the event will be available for at least 30 days post-event, allowing for continued engagement and outreach.
About Liquidia Corporation
Liquidia Corporation specializes in the development of groundbreaking therapies aimed at addressing rare cardiopulmonary diseases. Their focus includes the advances in treatments for pulmonary hypertension using their proprietary PRINT Technology. One notable achievement is YUTREPIA™ (treprostinil) inhalation powder, which has received approval for treating pulmonary arterial hypertension (PAH) as well as pulmonary hypertension linked to interstitial lung disease (PHILD). This innovative approach exemplifies the company’s commitment to improving patient outcomes.
In addition to YUTREPIA™, Liquidia is progressing with L606, an investigational sustained-release formulation of treprostinil. This drug is designed for twice-daily administration using a next-generation nebulizer system. Furthermore, the company has been active in the market with its generic Treprostinil Injection, which addresses the needs of PAH patients efficiently. Liquidia's dedication to research and development showcases their focus on utilizing advanced technologies to provide robust treatment options.
Company Contact Information
Investors:
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com
Media:
Patrick Wallace
Director, Corporate Communications
919.328.4383
patrick.wallace@liquidia.com
Frequently Asked Questions
What is the purpose of the Jefferies Global Healthcare Conference?
The Jefferies Global Healthcare Conference is designed to gather industry leaders and provide a platform for companies to present their latest developments and engage with investors.
How can interested individuals access the Liquidia presentation?
Individuals can access a live webcast of the presentation on Liquidia’s official website, as well as a recorded version available for 30 days after the event.
What is Liquidia Corporation known for?
Liquidia Corporation is recognized for developing innovative therapies for rare cardiopulmonary diseases, particularly using their proprietary PRINT Technology to enhance treatment efficacy.
What products does Liquidia currently market?
Liquidia currently markets YUTREPIA™, a medication approved for PAH, and also offers a generic version of Treprostinil Injection for PAH patients.
Who are the key speakers at the Liquidia presentation?
The key speakers at the Liquidia presentation will include CEO Dr. Roger Jeffs, CFO Michael Kaseta, and CBO Jason Adair, who will share insights into the company’s growth and strategy.
